title: Carrageenan-based gel retains limited anti-HIV-1 activity 8-24 hours after vaginal application by HIV-infected Thai women enrolled in a phase I safety trial.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Haaland
authors.forename: Thanyanan
authors.initials: T
authors.lastname: Chaowanachan
authors.forename: Tammy
authors.initials: T
authors.lastname: Evans-Strickfaden
authors.forename: Janneke H
authors.initials: JH
authors.lastname: van de Wijgert
authors.forename: Peter H
authors.initials: PH
authors.lastname: Kilmarx
authors.forename: Catherine A
authors.initials: CA
authors.lastname: McLean
authors.forename: Clyde E
authors.initials: CE
authors.lastname: Hart
mesh_terms: D000282:Administration, Intravaginal; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D002351:Carrageenan / Q000008:administration & dosage; D018592:Cross-Over Studies; D005260:Female; D005782:Gels; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D013785:Thailand; D007507:Therapeutic Irrigation; D013997:Time Factors; D014621:Vagina / Q000187:drug effects / Q000821:virology; D019562:Viral Load / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D005782:Gels; D002351:Carrageenan